Current use of rofecoxib (OR 1.71; 95% CI 1.33-2.18) and etoricoxib (OR 2.38; 95% CI 1.10-5.13), but not celecoxib, was associated with a significantly increased risk of ischemic stroke.
Case-Control (n=14,953)
Yes
Does the use of COX-2 selective NSAIDs increase the risk of ischemic stroke in patients prescribed NSAIDs?
Rofecoxib and etoricoxib, but not celecoxib, are associated with an increased risk of ischemic stroke, suggesting differing cerebrovascular safety profiles among COX-2 inhibitors.
Odds Ratio: 1.71 (95% CI 1.33–2.18)
BACKGROUND AND PURPOSE: Several randomized trials and a large number of epidemiological studies have provided evidence of an increased risk of acute myocardial infarction associated with the use of cyclooxygenase (COX)-2 selective nonsteroidal anti-inflammatory drugs (NSAIDs). Few data are available concerning the risk of ischemic stroke associated with COX-2 inhibitors. METHODS: We performed a nested case-control study in a cohort of 469,674 patients registered within the UK General Practice Research Database (GPRD), who had at least 1 prescription of an NSAID between June 1, 2000 and October 31, 2004. A total of 3094 cases with ischemic stroke were identified and 11 859 controls were matched on age, sex, year of cohort entry and general practice. Odds ratios (ORs) of ischemic stroke associated with the use of COX-2 selective NSAIDs were calculated by conditional logistic regression. RESULTS: Current use of rofecoxib (OR=1.71; 95% CI, 1.33 to 2.18), etoricoxib (OR=2.38; 95% CI, 1.10 to 5.13), but not of celecoxib (OR=1.07; 95% CI, 0.79 to 1.44) was associated with a significantly increased risk of ischemic stroke. For rofecoxib and etoricoxib, ORs tended to increase with higher daily dose and longer duration of use and were also elevated in patients without major stroke risk factors. CONCLUSIONS: Our study suggests that COX-2 selective NSAIDs differ in their potential to cause ischemic cerebrovascular events. An increased risk of ischemic stroke may be influenced by additional pharmacological properties of individual COX-2 inhibitors.
Andersohn et al. (Fri,) conducted a case-control in Ischemic stroke (n=14,953). COX-2 selective NSAIDs (rofecoxib, etoricoxib, celecoxib) vs. Matched controls was evaluated on Ischemic stroke (OR 1.71, 95% CI 1.33 to 2.18). Current use of rofecoxib (OR 1.71; 95% CI 1.33-2.18) and etoricoxib (OR 2.38; 95% CI 1.10-5.13), but not celecoxib, was associated with a significantly increased risk of ischemic stroke.